BMRN logo

BioMarin Pharmaceutical Inc.

BMRN
Healthcare|Biotechnology|US
$56.03
-0.09 (-0.16%)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80

About

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

Stock Price

+8.1%(1Y)
1M
+2.1%
3M
-12.2%
6M
+3.6%
YTD
-5.7%
1Y
+6.4%
3Y
-34.5%
5Y
-32.8%

Pipeline Summary

179 total trials
30
Phase 1
54
Phase 2
34
Phase 3
10
Phase 4
Completed: 105By Invitation: 5Active: 14Terminated: 29Approved: 3Unknown: 5Recruiting: 12Withdrawn: 5No Longer Available: 1

Active Trials (26)

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907Hemophilia A
Phase 3Active
Enrollment: 6 participants
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
NCT04554940Achondroplasia
Phase 2Active
Enrollment: 20 participants
Achondroplasia Natural History Multicenter Clinical Study
NCT02597881Achondroplasia
Recruiting
Enrollment: 1,500 participants
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979Idiopathic Short Stature
Recruiting
Enrollment: 300 participants
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
NCT05121376Hereditary Angioedema
Phase 1Phase 2Active
Enrollment: 44 participants

BioScore

5.7/10
Watchlist

Key Facts

Market Cap$10.85B
Employees3,221 (+6% YoY)
CEOAlexander Hardy
IPO DateJul 26, 1999
Beta0.21
52-Week Range$49.26 – $70.98
Avg Volume2,151,663
ExchangeNASDAQ

Ownership

Float99.6%
Shares Outstanding193.6M

Recent Insider Trades

Friberg Gregory RTAX W/H
Sep 30, 20264,086 shares @ $60.00
Plenge Robert MAWARD
Sep 10, 20266,140 shares
Plenge Robert MOTHER
Sep 10, 20260 shares
Davis George EricSELL
Sep 2, 202617,557 shares @ $66.28
Countouriotis AthenaAWARD
Jun 2, 20267,490 shares

Peers

ALNYAlnylam Pharmaceuticals, Inc.
$20.89B
ASNDAscendis Pharma A/S
$16.90B
BBIOBridgeBio Pharma, Inc.
$14.47B
INSMInsmed Incorporated
$25.10B
IONSIonis Pharmaceuticals, Inc.
$6.55B
PHARPharming Group N.V.
$869.9M
PTCTPTC Therapeutics, Inc.
$5.47B
RAREUltragenyx Pharmaceutical Inc.
$1.52B
Data last updated: Nov 9, 2026, 04:00 AM